Another study examined the relationship between subjective cognitive decline (SCD) participants and the impact of APOE disclosure on psychological and behavioral outcomes and found that the presence of SCD did not exacerbate the AD risk‐related distress following the announcement that one was a ε4 carrier [58]. The gene discussed is APOE; the disease is Alzheimer disease.